Review On Analytical Method for Determination of Sitagliptin Phosphate in Bulk and In Different Dosage Forms
Nusratbanu K. Shaikh*, Darshil B. Shah, Dilip G. Maheshwari
Dipeptidyl peptidase-4 inhibitors (DPP-4s), also called as gliptins, are a relatively new class of drugs to treat type 2 diabetes. Sitagliptin phosphate competitively inhibit dipeptidyl peptidase-4 (DPP-4). This enzyme breakdown the incretins GLP-1, gastrointestinal hormones released in response to a meal. By preventing GLP-1 inactivation, they are able to increase the secretion of insulin and suppress the release of glucagon by the alpha cells of pancreas. This leads blood glucose level to normal. It also opens new gateways for a personalized medicine in patients with Type 2 diabetes and it also offers various merits when compared to other glucose-lowering agents. Despite they have been commercialized since a few years only, available data obtained in randomized controlled trials are of better quality compared to those available with classical glucose-lowering agents, especially in elderly people who have suffering from renal impairment or at high cardiovascular risk and patients at higher risk of hypoglycemia. But, their remaining uncertainties and controversies that should be resolved by further ongoing large prospective controlled trials and increasing clinical experience combined with a careful post-marketing surveillance. The clinical and pharmaceutical analysis of these drugs requires effective analytical procedures for quality control and pharmacodynamic and pharmacokinetic studies as well as stability study. There are many analytical methods reported so far in the literature for the determination of Sitagliptin phosphate in Biological samples and pharmaceutical formulations. This article narrates different chromatographic (HPLC, HPTLC, UPLC, LC) & different spectrophotometric method (UV) for Sitagliptin single drug as well as combination with other drug.
Share this article